These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25434052)

  • 1. Orphan drugs: expensive yet necessary.
    Hyry HI; Roos JC; Cox TM
    QJM; 2015 Apr; 108(4):269-72. PubMed ID: 25434052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limits on use of health economic assessments for rare diseases.
    Hyry HI; Stern AD; Cox TM; Roos JC
    QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. For the Sake of Justice: Should We Prioritize Rare Diseases?
    Juth N
    Health Care Anal; 2017 Mar; 25(1):1-20. PubMed ID: 25145639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationing of drugs for rare diseases.
    Hughes D
    Pharmacoeconomics; 2006; 24(4):315-6. PubMed ID: 16605277
    [No Abstract]   [Full Text] [Related]  

  • 7. Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey.
    Dragojlovic N; Rizzardo S; Bansback N; Mitton C; Marra CA; Lynd LD
    Patient; 2015 Feb; 8(1):93-101. PubMed ID: 25586645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
    Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
    Schlander M; Beck M
    Curr Med Res Opin; 2009 May; 25(5):1285-93. PubMed ID: 19366306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
    Mentzakis E; Stefanowska P; Hurley J
    Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Orphan drugs: drugs for rare diseases].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
    [No Abstract]   [Full Text] [Related]  

  • 17. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orphan drugs and the NHS: should we value rarity?
    McCabe C; Claxton K; Tsuchiya A
    BMJ; 2005 Oct; 331(7523):1016-9. PubMed ID: 16254305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orphan drug policies and use in pediatric nephrology.
    Karpman D; Höglund P
    Pediatr Nephrol; 2017 Jan; 32(1):1-6. PubMed ID: 27738765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the clinical cost of drug development for orphan versus non-orphan drugs.
    Jayasundara K; Hollis A; Krahn M; Mamdani M; Hoch JS; Grootendorst P
    Orphanet J Rare Dis; 2019 Jan; 14(1):12. PubMed ID: 30630499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.